The girl’s illness was unusually severe. Laboratory testing showed she carried two distinct disease-driving antibodies at once: myeloperoxidase-ANCA and proteinase 3-ANCA, a dual positivity found in only about 13 percent of pediatric cases. Her kidneys were under attack, with heavy proteinuria peaking at a spot urinary protein-to-creatinine ratio of 2,018.6 mg/g, a level indicating significant glomerular injury. Most alarming was the lung hemorrhage, which in vasculitis signals active inflammation of the pulmonary capillaries. Simply stopping the offending drug, the standard first move in drug-induced autoimmunity, proved insufficient. Her disease remained clinically active, forcing her medical team to escalate to pulsed intravenous methylprednisolone, a high-dose corticosteroid regimen designed to rapidly suppress the immune storm, followed by seven cycles of cyclophosphamide, a potent chemotherapy agent repurposed as an immunosuppressant, at a cumulative dose of 164.7 mg per kilogram of body weight.

What makes the case scientifically interesting is what happened next. Even after the drug was withdrawn and aggressive immunosuppression delivered, the autoimmune process did not switch off on its own schedule. The authors argue this pattern is consistent with autonomous autoimmunity, meaning the immune response, once triggered, sustains itself independently of the original chemical trigger. The observation carries a practical warning for clinicians: pediatric antithyroid drug-induced vasculitis cannot always be managed by drug withdrawal alone, and severe presentations such as diffuse alveolar hemorrhage demand the same aggressive immunosuppressive protocols used for primary, non-drug-induced forms of the disease. The authors are careful to note that this inference rests on limited observational evidence rather than controlled trials, a caveat that applies to nearly everything known about this rare condition.

To place their patient in context, the team systematically searched PubMed through September 2026 and the Chinese databases CNKI and Wanfang, identifying 37 published studies describing 53 pediatric cases of antithyroid drug-induced ANCA-associated vasculitis in patients aged 18 or younger. Adding their index case brought the combined dataset to 54 children treated between 1994 and 2026. The demographic profile is striking: 85.2 percent were female and the mean age was 13.0 years, with a range of 7 to 18. This female predominance mirrors the epidemiology of Graves’ disease itself, which disproportionately affects adolescent girls, since only children receiving antithyroid drugs are at risk of the complication. The long time span reflects growing recognition of the syndrome since the first reports appeared three decades ago.

The organ-by-organ breakdown of the 54 cases reveals a disease that behaves much like its adult counterpart. Renal involvement was the most common manifestation, affecting 74.1 percent of children, typically as a pauci-immune glomerulonephritis in which inflammatory damage to the kidney’s filtering units causes blood and protein to leak into the urine. Cutaneous involvement, often as palpable purpura or ulcerating skin lesions, affected 42.6 percent, while pulmonary disease, ranging from cough and hemoptysis to life-threatening alveolar hemorrhage, affected 37.0 percent. The triad of kidney, skin and lung involvement reflects the underlying pathology: ANCA-activated neutrophils attacking small vessels wherever they cluster, and the kidneys, with their dense capillary networks, bearing the heaviest burden.

Outcomes across the dataset were mixed but mostly favorable. Complete remission was achieved in 32 of the 54 children, or 59.3 percent, while 18, or 33.3 percent, achieved partial remission, a group that included one patient who progressed to end-stage renal disease, the permanent loss of kidney function requiring dialysis or transplantation. Three children died, a mortality of 5.6 percent, and one was lost to follow-up. These figures underscore that although drug-induced vasculitis is often assumed to be milder than the primary autoimmune form, in children it can be lethal or organ-threatening, particularly when the lungs or kidneys are involved. The review also highlights a striking gap in management: definitive treatment of the underlying Graves’ disease with radioactive iodine-131 during active vasculitis was reported in only two pediatric cases, one of which is the present index patient.

The use of iodine-131 in this girl’s case deserves particular attention. Antithyroid drugs work by blocking hormone synthesis, but in patients who develop vasculitis they become the enemy, leaving clinicians with a dilemma: the hyperthyroidism still needs definitive treatment, yet the standard medications are now contraindicated. Radioactive iodine offers an alternative, destroying the overactive thyroid tissue through targeted beta radiation, but administering it while the immune system is in open revolt against blood vessels is a decision few teams have made. The successful use of iodine-131 ablation in this patient, alongside her immunosuppressive therapy, suggests it may be a feasible definitive option in selected children, though with only two published pediatric precedents the evidence base remains thin and the authors frame it as a consideration for specific cases rather than a general recommendation.

Perhaps the most conceptually intriguing finding is what the follow-up revealed about antibodies. At 18 months, the girl’s clinical disease had resolved completely: the lung hemorrhage and proteinuria were gone. Yet her myeloperoxidase-ANCA remained persistently positive even as the proteinase 3-ANCA had normalized. This mismatch between laboratory markers and clinical state, termed serological-activity dissociation, is a recognized phenomenon in ANCA-associated vasculitis but is poorly characterized in children. It matters practically because physicians often use ANCA titers to gauge disease activity and guide treatment decisions. If antibodies can persist for years after the disease has burned out, treating the number rather than the patient risks unnecessary immunosuppression, with all its infectious and toxic costs, in a child who is actually in remission.

The broader significance of the report lies in its timing and its population. Propylthiouracil-induced vasculitis is well documented in adults, but pediatric data have been scattered across case reports for three decades without systematic synthesis. By pooling 54 cases, the study establishes benchmarks for frequency of organ involvement, dual antibody positivity, remission rates and mortality that clinicians can use when counseling families and weighing treatment choices. It also feeds into an ongoing debate about antithyroid drug safety in children: propylthiouracil carries a known risk of severe liver injury as well as vasculitis, while methimazole, the other first-line agent, has its own teratogenic profile, leaving pediatric endocrinologists to navigate a genuinely difficult risk landscape when treating adolescent Graves’ disease.

For now, the girl at the center of the report is doing well, her lungs clear and her kidneys recovered, her thyroid definitively ablated, her antibodies a lingering molecular echo of an illness her immune system has otherwise forgotten. Her case adds a data point to a rare disease and a caution to a common practice: the drugs that quiet an overactive thyroid can, in a small fraction of children, ignite an autoimmune fire that no longer needs them to keep burning. The authors’ synthesis of three decades of published cases gives pediatricians both a map of that fire and, in persistent antibody positivity, a reminder that the laboratory and the bedside do not always tell the same story.

Subject of Research: Propylthiouracil-induced ANCA-associated vasculitis in children with Graves' disease

Article Title: Pediatric antithyroid drug-induced ANCA-associated vasculitis: disease persistence, serological-activity dissociation, and the role of ¹³¹I therapy — a case report of propylthiouracil-induced diffuse alveolar hemorrhage and systematic review of 53 published pediatric cases

Article References: Wu, P., Chen, Z., & Xiao, Y. (2026). Pediatric antithyroid drug-induced ANCA-associated vasculitis: disease persistence, serological-activity dissociation, and the role of ¹³¹I therapy — a case report of propylthiouracil-induced diffuse alveolar hemorrhage and systematic review of 53 published pediatric cases. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07801-7

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07801-7

Keywords: propylthiouracil, ANCA-associated vasculitis, pediatrics, Graves' disease, diffuse alveolar hemorrhage, MPO-ANCA, PR3-ANCA, radioactive iodine-131, cyclophosphamide, systematic review, microscopic polyangiitis, serological-activity dissociation

ANCA-associated vasculitis, or AAV, is a family of necrotizing small-vessel diseases driven by pathogenic antineutrophil cytoplasmic antibodies. It encompasses microscopic polyangiitis, granulomatosis with polyangiitis, and eosinophilic granulomatosis with polyangiitis. Classically, patients present with striking systemic features—rapidly rising creatinine, pulmonary hemorrhage, palpable purpura, peripheral neuropathy—that trigger an immunological workup and serological testing. Bronchiectasis, by contrast, is rarely considered an inaugural manifestation. When it appears in AAV, it is usually interpreted as structural fallout from established vasculitic inflammation rather than a warning shot, a framing that can postpone ANCA testing until organ damage declares itself elsewhere.

The patient at the center of the report arrived in 2018 with a chronic productive cough and a history of intermittent asthma. High-resolution computed tomography revealed focal bronchiectasis confined to the right middle lobe. Her physicians did what good diagnosticians do: they systematically excluded the usual suspects. Serial sputum cultures and bronchoalveolar lavage were negative for bacterial, mycobacterial, and fungal pathogens. Non-tuberculous mycobacterial infection, cystic fibrosis, primary immunodeficiency, allergic bronchopulmonary aspergillosis, and eosinophilic granulomatosis with polyangiitis were all ruled out. Spirometry was normal. Empiric corticosteroids and macrolides were prescribed for presumed non-infective airway inflammation, and her symptoms improved—but never resolved.

Over the following six years, repeat imaging charted a slow, ominous march. The focal right middle lobe disease progressed to multifocal bilateral bronchiectasis, accompanied by tree-in-bud nodularity and mucus plugging, with new parenchymal nodules appearing along the way. Her antinuclear antibody test was negative. Critically, ANCA serology was never obtained, and the diagnosis remained bronchiectasis of undetermined etiology for seven years. The authors of the report are careful not to overclaim causality, but they highlight a stark, narrower fact: seven years elapsed during which an inexpensive blood test that would have reframed the entire diagnosis was never sent.

Then, in 2025, the systemic disease erupted. The woman developed palpable purpura across both lower extremities, hemoptysis, and hematuria. Imaging showed new multifocal bilateral consolidations superimposed on the established bronchiectasis, though without the ground-glass pattern of diffuse alveolar hemorrhage; her hemoglobin and oxygen saturation remained stable and the hemoptysis resolved spontaneously. Her kidneys told a more urgent story. Serum creatinine had surged from 0.46 mg/dL six weeks earlier to 2.09 mg/dL—an estimated glomerular filtration rate collapsing from 100 to 24 mL/min/1.73 m²—and reached a nadir of 2.19 mg/dL on hospital day three, all while urine output remained preserved.

The serology finally caught up with the disease. Indirect immunofluorescence showed a perinuclear pattern, and antigen-specific ELISA confirmed myeloperoxidase-ANCA, or MPO-ANCA, at 250.2 U/mL against a reference value below 1.0, with proteinase 3-ANCA negative. Urinalysis revealed proteinuria with dysmorphic erythrocytes. A renal biopsy sampling fourteen glomeruli showed pauci-immune crescentic glomerulonephritis with a cellular crescent in one glomerulus, no immune deposits, and more than half of the glomeruli intact—Berden focal class, the histological category carrying the most favorable prognosis. Anti-glomerular basement membrane and anti-double-stranded DNA antibodies were negative, and complement was normal. Together, the findings established microscopic polyangiitis.

Treatment followed current guidelines: three days of intravenous methylprednisolone at 500 mg daily, an oral prednisone taper, and rituximab 1 gram repeated after two weeks and then every six months as maintenance, with Pneumocystis prophylaxis. The response was dramatic on the inflammatory front. Within two months her eGFR peaked at 74, stabilizing at 60 at fifteen months—stage 3a chronic kidney disease, a plateau the authors attribute to residual nephron loss after inflammatory suppression. At five months, high-resolution CT showed near-complete resolution of the consolidations, while the underlying bronchiectasis persisted, exactly as expected for fixed structural airway damage. MPO-ANCA fell from 250.2 to 5.2 U/mL by twelve months with documented B-cell depletion, and she remains asymptomatic at fifteen months, her cough finally resolved.

The literature review embedded in the report gives the case its wider significance. A 2024 systematic review and meta-analysis of 24 studies found a pooled bronchiectasis prevalence of 19 percent in AAV—higher with MPO-ANCA than PR3-ANCA, at 28 percent versus 13 percent—and noted that bronchiectasis may precede, coincide with, or follow the vasculitis. One retrospective cohort of 58 AAV patients found bronchiectasis in 37.9 percent, all MPO-ANCA positive, independently associated with MPO specificity, female sex, and age at diagnosis. Most striking is a multicentre cohort of 61 patients with AAV and bronchiectasis: in 25 of them, bronchiectasis preceded the vasculitis by a median of 16 years, and this bronchiectasis-first group had more microscopic polyangiitis, more MPO-ANCA, and shorter survival. The present patient—female, MPO-positive, with airway disease antedating systemic vasculitis by seven years—fits that phenotype precisely.

Yet the authors resist a simple causal narrative, and the evidence supports their caution. Where bronchiectasis was universally MPO-associated, affected patients actually had less frequent renal involvement than those without it, and bronchiectasis in AAV generally does not respond to immunosuppression—consistent with this patient, whose consolidations melted away while the structural airway disease remained. Whether earlier serology would have changed her outcome is genuinely uncertain. The real gap, they argue, lies in the current diagnostic algorithms. The 2025 European Respiratory Society guideline strongly recommends standardized testing for the underlying cause of bronchiectasis, but ANCA appears only within an etiological algorithm gated behind systemic features—coexisting autoimmune disease, hemoptysis, or signs of vasculitis—and the guideline explicitly states these components are not separate recommendations. A 2025 observational study screening 468 bronchiectasis patients found ANCA positivity in just 3.8 percent and concluded screening should remain individualized. The 2026 American College of Chest Physicians guideline addresses management only. This patient had none of the trigger features before 2025: her gap sits outside current algorithms—culture-negative, radiographically progressive, incompletely corticosteroid-responsive disease without systemic features.

One diagnostic alternative deserved careful exclusion. The combination of MPO-ANCA positivity, long-standing airway disease, and a history of asthma raises eosinophilic granulomatosis with polyangiitis as the leading rival. Applying the 2022 ACR/EULAR classification criteria is instructive: her cumulative score was just 2 points—3 for obstructive airway disease, credited on her asthma history despite normal spirometry, minus 1 for hematuria—far below the 6 required, because the most heavily weighted item, a maximum eosinophil count of at least 1 × 10⁹ per liter, was never met. Eosinophils were 0 percent at presentation and had never been elevated; total IgE, measured in 2024, was 114 kU/L without the marked elevation characteristic of EGPA. Pauci-immune crescentic glomerulonephritis with markedly elevated MPO-ANCA and no tissue or blood eosinophilia settles the question in favor of microscopic polyangiitis. The case also carries a technical lesson in serology: the discordance between her falling MPO-ANCA titers and persistent weak immunofluorescence positivity is compatible with non-MPO perinuclear antibodies during B-cell depletion, reinforcing guidance against basing treatment decisions on titers alone. Limitations remain—alveolar hemorrhage was never definitively confirmed, and the absence of ANCA testing during the airway phase means the timing of seroconversion is unknown. What endures is the clinical message: in a patient with progressive, culture-negative bronchiectasis that resists the usual treatments, the vasculitis may already be knocking, years before the door gives way.

Subject of Research: Bronchiectasis as an early sentinel manifestation of ANCA-associated vasculitis

Article Title: Bronchiectasis as the Sentinel Manifestation of ANCA‐Associated Vasculitis: A Case Report and Literature Review

Article References: Kim, A., Vartany, C., Hegde, S., Lau, K., Tatosyan, L., & Liang, B. (2026). Bronchiectasis as the Sentinel Manifestation of ANCA ‐Associated Vasculitis: A Case Report and Literature Review. Respirology Case Reports, 14(10), Article e70777. https://doi.org/10.1002/rcr2.70777

Image Credits: AI Generated

DOI: 10.1002/rcr2.70777

Keywords: bronchiectasis, ANCA-associated vasculitis, microscopic polyangiitis, MPO-ANCA, case report, glomerulonephritis, rituximab, high-resolution CT, EGPA, clinical guidelines, autoimmune screening, respiratory medicine